You'd think that things might slow down over a long holiday weekend, but ETF issuers kept their foot on the gas. Perusing through recent SEC filings (and who doesn't do that just for fun!), there were several for new ETFs coming down the pike, including a group of new global/international funds from Franklin Templeton, the latest biotech-focused ETF from Loncar, who already has the Cancer Immunotherapy ETF (CNCR), and a trio of new funds from Global X.Franklin TempletonThe four Franklin funds - the Franklin LibertyQ International Equity Hedged ETF (FLQH), Franklin LibertyQ Emerging Markets ETF (FLQE), Franklin LibertyQ Global Dividend ETF (FLQD), Franklin LibertyQ Global Equity ETF (FLQG) - will use a multi-factor approach and charge between 0.35% and 0.55% annually.LoncarThe Loncar China BioPharma ETF (CHNA) will include only (i) companies whose locations are exclusively in China and (ii) for companies with locations both in and outside China, companies (a) whose key operations and/or research and development facilities are located in China or (b) for which at least 25% of the value of their product pipeline is directly tied to the Chinese market. Its expense ratio is unknown.Global XThe Global X Genomics ETF will target companies involved in gene editing, genomic sequencing, genetic medicine/therapy, and computational genomics. The Global X E-commerce ETF will invest in companies that are positioned to benefit from the increased adoption of e-commerce as a distribution model, including but not limited to companies that operate platforms that connect buyers and sellers, companies that provide e-commerce software and services, and companies that derive a significant portion of overall revenue from online sales. The underlying index of the Global X Adaptive U.S. Factor ETF is designed to dynamically allocate across three sub-indices that provide exposure to U.S. equities that exhibit characteristics of one of three primary factors: value, momentum and low volatility.